Single-Reaction, Multiplex, Real-Time RT-PCR for the Detection, Quantitation, and Serotyping of Dengue Viruses

Jesse Waggoner, Emory University
Janaki Abeynayake, Stanford University
Malaya K. Sahoo, Stanford University
Lionel Gresh, Sustainable Sciences Institute
Yolanda Tellez, Ministry of Health, Nicaragua
Karla Gonzalez, Ministry of Health, Nicaragua
Gabriela Ballesteros, Ministry of Health, Nicaragua
Anna M. Pierro, St. Orsola-Malpighi University Hospital
Paolo Gaibani, St. Orsola-Malpighi University Hospital
Frances P. Guo, Stanford University

Only first 10 authors above; see publication for full author list.

Journal Title: PLoS Neglected Tropical Diseases
Volume: Volume 7, Number 4
Publisher: Public Library of Science | 2013-04-01, Pages e2116-e2116
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1371/journal.pntd.0002116
Permanent URL: https://pid.emory.edu/ark:/25593/rr2kt

Final published version: http://dx.doi.org/10.1371/journal.pntd.0002116

Copyright information:
© 2013 Waggoner et al.

Accessed June 10, 2018 12:02 AM EDT
Introduction

Dengue results from infection with one of four closely related serotypes of dengue virus (DENV), the most common vector-borne human pathogen worldwide. These serotypes are designated DENV-1, -2, -3, and -4, and they are transmitted by the mosquitoes Aedes aegypti and Aedes albopictus, which reside in tropical and sub-tropical areas of the world [1]. Infection with one serotype (primary infection) results in immunity to that serotype, but infection can occur with any of the remaining serotypes (secondary infection). Secondary DENV infection has been shown to be a significant risk factor for the development of severe disease, including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [1–4]. Recent reports estimate that 230 million DENV infections occur annually, including 2 million cases of severe disease and 21,000 deaths [5]. Over 3.6 billion people live in endemic regions and are at risk for infection [5].

A large number of assays and testing platforms have been developed for the diagnosis of DENV infections, though available tests remain suboptimal [1]. Viral isolation continues to be performed in some laboratories, though the prolonged turnaround time precludes its utility for clinical diagnosis. Anti-DENV IgM antibodies do not become detectable until at least the third day of clinical illness, and IgM tests are not reliably positive until...
Dengue, or break-bone fever, is the most common mosquito-borne viral disease of humans with over half the world’s population at risk for infection. Dengue has a wide spectrum of clinical manifestations, from self-limit fever to fatal hypovolemic shock, and because of this, dengue is difficult to distinguish from many other infections based on clinical characteristics alone. Diagnostic testing is therefore critical to accurately identify dengue virus (DENV)-infected patients and also rule out dengue in patients with undifferentiated fever.

Unfortunately, current diagnostics for early DENV detection consist of point-of-care or laboratory-based antigen tests that lack sensitivity or molecular assays that are laborious to perform or lack the test characteristics necessary for routine use. To address these limitations, we developed a single-reaction, multiplex, real-time RT-PCR for the detection, quantitation, and serotyping of dengue viruses from patient serum or plasma. We demonstrate that this diagnostic test is more analytically sensitive than a commonly used reference molecular assay, and is able to detect viral RNA and provide serotype information in specimens collected more than 5 days after fever onset and from patients who had already developed anti-DENV IgM antibodies. This unique combination of sensitivity and serotyping capability in a simple, single-reaction format represents a step forward in dengue diagnostics.

Dengue Virus Sequences and Assay Design

Publicly available DENV sequences were obtained from GenBank, accessed in August 2011. For DENV-1, -2, and -3, sequences deposited since 1990 were selected and up to 2 sequences per country per year were included (143 DENV-1 sequences, 181 DENV-2 sequences, 191 DENV-3 sequences). Due to the lower number of deposited sequences for DENV-4, all complete genome sequences available for this serotype (75 DENV-4 sequences) were included. Sequences listed as sylvatic strains were excluded. Segments of these genomes were aligned using MegAlign software (DNAStar; Madison, WI). A consensus sequence was generated for each serotype that showed bases conserved across >95% of sequences included in the alignment. This identified a region of the 5' UTR and capsid gene that was highly conserved within each DENV serotype.

Using the 95% consensus sequence, Beacon Designer software (Premier Biosoft; Palo Alto, CA) was used to generate primer and probe sets directed against segments of the 5' UTR and capsid gene for all four serotypes. These were tested using control genomic RNA for DENV-1, -2, -3, and -4, and based on initial results, primer and probe sets patterned on those for DENV-1 were generated for DENV-2, -3, and -4 using Primer3 software. The primer and probe sequences are listed in Table 1 and Table 2, respectively. The primers and probes were tested in silico using BLASTn to query the NCBI nucleotide database. Searches excluding the DENV group (taxid: 11052) were also performed to identify the best non-DENV sequence matches in the database as well as in the Flaviviridae family.

RT-PCR and Internal Control Assays

The DENV multiplex rRT-PCR was performed using the SuperScript III Platinum One-Step qRT-PCR kit (Invitrogen; Carlsbad, CA). Reaction mixtures were scaled from the manufacturer-recommended 50 μL volume to 25 μL per reaction. Each reaction contained 300 nM primers for DENV-1, -2, and -3 and 450 nM primers for DENV-4. Each probe was added to 600 nM RT-PCR assays utilizing real-time chemistry have been published previously, but to our knowledge only two have been directly compared to another nucleic acid amplification test, both to a version of the hemi-nested RT-PCR assay [12,16]. Furthermore, in both of these reports, by Johnson, et al. and Chien, et al., the single-reaction, multiplex assays proved less sensitive [12,16,27]. For this reason, the hemi-nested RT-PCR, previously modified to improve its sensitivity, was selected for use as reference [12].

This study describes the design and evaluation of a single-reaction, multiplex, quantitative rRT-PCR assay for the detection and serotyping of dengue viruses from patient samples. This assay targets the 5' untranslated region (UTR) and capsid gene of DENV and utilizes four molecular beacons for detection and serotyping. Beacons were chosen for their high sensitivity and ability to differentiate sequences differing by as few as one or two bases [29]. This assay is shown to be more sensitive, both analytically and clinically, than the reference hemi-nested RT-PCR. It is also specific for dengue viruses, demonstrating no amplification when tested against the genomic RNA of other flaviviruses as well as samples from domestic (USA) patients without risk of DENV exposure. This assay represents an improvement over previously reported DENV rRT-PCRs as it maintains the sensitivity and serotyping capability of the reference molecular diagnostic test while also providing viral load monitoring and improved workflow in a simple, single-reaction format.

Methods

Publicly available DENV sequences were obtained from GenBank, accessed in August 2011. For DENV-1, -2, and -3, sequences deposited since 1990 were selected and up to 2 sequences per country per year were included (143 DENV-1 sequences, 181 DENV-2 sequences, 191 DENV-3 sequences). Due to the lower number of deposited sequences for DENV-4, all complete genome sequences available for this serotype (75 DENV-4 sequences) were included. Sequences listed as sylvatic strains were excluded. Segments of these genomes were aligned using MegAlign software (DNAStar; Madison, WI). A consensus sequence was generated for each serotype that showed bases conserved across >95% of sequences included in the alignment. This identified a region of the 5' UTR and capsid gene that was highly conserved within each DENV serotype.

Using the 95% consensus sequence, Beacon Designer software (Premier Biosoft; Palo Alto, CA) was used to generate primer and probe sets directed against segments of the 5' UTR and capsid gene for all four serotypes. These were tested using control genomic RNA for DENV-1, -2, -3, and -4, and based on initial results, primer and probe sets patterned on those for DENV-1 were generated for DENV-2, -3, and -4 using Primer3 software. The primer and probe sequences are listed in Table 1 and Table 2, respectively. The primers and probes were tested in silico using BLASTn to query the NCBI nucleotide database. Searches excluding the DENV group (taxid: 11052) were also performed to identify the best non-DENV sequence matches in the database as well as in the Flaviviridae family.
Table 1. Primer sequences for the DENV multiplex rRT-PCR.

<table>
<thead>
<tr>
<th>Name</th>
<th>Primer Sequence (5’→3’)</th>
<th>Genomic Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>DENV-1, 2, 3 Forward</td>
<td>CAGATCTCTGTATGAAACCAACCACG</td>
<td>86–109</td>
</tr>
<tr>
<td>DENV-2 Forward C→T</td>
<td>CAGATCTCTGTATGAAACCAACCACG</td>
<td>87–110</td>
</tr>
<tr>
<td>DENV-3 Forward C→T</td>
<td>CAGATCTCTGTATGAAACCAACCACG</td>
<td>85–108</td>
</tr>
<tr>
<td>DENV-4 Forward</td>
<td>GATCTCTGAAAATGAACCAACCACG</td>
<td>81–99</td>
</tr>
<tr>
<td>DENV-1, 3 Reverse</td>
<td>TTTGAGAATCTCTTCGCCAAC</td>
<td></td>
</tr>
<tr>
<td>DENV-2 Reverse A→G</td>
<td>AGTCAGACCGCGGTCTTCTCT</td>
<td>171–152</td>
</tr>
<tr>
<td>DENV-4 Reverse</td>
<td>AGAATTCTTTCCACCAACC</td>
<td>190–173</td>
</tr>
</tbody>
</table>

Genomic locations are provided for the 5’ base of each primer based on reference virus sequences: DENV-1, US/Hawaii/1944 (GenBank: EU848545.1); DENV-2, New Guinea C Strain (GenBank: AF308403.1); DENV-3, strain H87 (GenBank: M93130.1); DENV-4, strain H241 (GenBank: AY947539.1). Predicted amplicon sizes are as follows: DENV-1, 114 bp; DENV-2, 85 bp; DENV-3, 114 bp; DENV-4, 110 bp.

Table 2. Probe sequences for the DENV multiplex rRT-PCR.

<table>
<thead>
<tr>
<th>Channel</th>
<th>5’ Fluor</th>
<th>Probe Sequence (5’→3’)</th>
<th>3’ Quencher</th>
</tr>
</thead>
<tbody>
<tr>
<td>Green</td>
<td>FAM</td>
<td>CGCGATCGGTTCGCAGATTTGAAGACCGGATCGCG</td>
<td>BHQ-1</td>
</tr>
<tr>
<td>Yellow</td>
<td>CAL Fluor Orange 560</td>
<td>CGCGATCGGTTCGCAGATTTGAAGACCGGATCGCG</td>
<td>BHQ-1</td>
</tr>
<tr>
<td>Orange</td>
<td>CAL Fluor Red 610</td>
<td>CGCGATCGGTTCGCAGATTTGAAGACCGGATCGCG</td>
<td>BHQ-2</td>
</tr>
<tr>
<td>Red</td>
<td>Quasar 670</td>
<td>CGCGATCGGTTCGCAGATTTGAAGACCGGATCGCG</td>
<td>BHQ-2</td>
</tr>
</tbody>
</table>

Probes are listed by the channel in which signal is detected on the Rotor-Gene Q instrument. Underlined probe segments designate sequences complementary to the DENV consensus; segments on the 5’ and 3’ ends of the probe comprise the beacon stem.

doi:10.1371/journal.pntd.0002116.t002

doi:10.1371/journal.pntd.0002116.t003

doi:10.1371/journal.pntd.0002116.t001

doi:10.1371/journal.pntd.0002116.t000

doi:10.1371/journal.pntd.0002116.t004

doi:10.1371/journal.pntd.0002116.t005

doi:10.1371/journal.pntd.0002116.t006
previously described, though the protocol was modified for this study [29]. RT-PCR was carried out with SuperScript III Platinum One-Step qRT-PCR (Invitrogen; Carlsbad, CA) and the same cycling conditions as the multiplex DENV rRT-PCR were used. The reaction volume was scaled to 25 μL, and the final reaction mixture contained 200 nM forward and reverse primers and 100 nM probe.

**Reference Virus RNA**

Genomic RNA from control strains of the four DENV serotypes, DENV-1 Hawaii 1944, DENV-2 New Guinea C strain, DENV-3 strain H87, and DENV-4 strain H241 were obtained from Virxcell (Grenada, Spain). Genomic RNA of three strains of West Nile Virus (WNV, NY 1999; clinical isolate, previously reported as NAL strain; and B956), and a single strain each of Japanese Encephalitis Virus (JEV) and Tick-Borne Encephalitis Virus (TBEV) were obtained from the St. Orsola-Malpighi Hospital, Regional Reference Center for Microbiological Emergencies (Bologna, Italy) [30].

**Plasmid Generation, Quantitation, and Sequencing**

The amplicons generated by the rRT-PCR assay for control strains of DENV and selected clinical specimens were cloned using the TOPO TA Cloning Kit with PCR 2.1 TOPO (Invitrogen; Carlsbad, CA). RT-PCR was performed as described above, except that reactions were carried out in a DNA Engine Thermal Cycler (Bio-Rad; Hercules, CA) without probes. Amplicons were detected by 2% agarose gel electrophoresis, and 2 μL of each PCR reaction was used in the cloning reaction. The presence of the cloned insert was confirmed by PCR using the Fermentas 2× PCR Master Mix (Fermentas; Glen Burnie, MD) and the same mix of DENV primers used in the rRT-PCR. Two μL of culture broth was boiled and cooled, then included in PCR reactions otherwise performed according to the manufacturer’s recommendations. Cycling conditions included an initial hold at 94°C for 2 min, followed by 45 cycles of 94°C for 15 sec, 55°C for 30 sec, and 68°C for 30 sec. Amplicons were detected by 2% agarose gel electrophoresis. Plasmids were extracted using the GeneJET Plasmid Miniprep Kit (Fermentas; Glen Burnie, MD). The concentration of plasmid DNA was quantified using the AccuBlue High Sensitivity dsDNA Quantitation Kit (Biotium Inc.; Hayward, CA). Twenty-five-, 50-, and 100-fold dilutions were tested in triplicate. A standard curve was generated and the concentration of plasmid in the initial eluate calculated. Plasmids were sequenced by bi-directional dideoxynucleotide termination sequencing using M13 forward and reverse primers (Elim Biopharmaceuticals, Inc.; Hayward, CA).

**Multiplex rRT-PCR Linearity, Lower Limit of Detection, and Precision**

The analytical evaluation of the DENV multiplex rRT-PCR was performed according to previously published recommendations [31]. For each serotype, linearity studies were performed on serial 10-fold dilutions of both quantified plasmid DNA and reference RNA. For the plasmid DNA, dilutions from 7.0 log10 copies/μL to 1 copy/μL were tested in triplicate on a single run. The concentrations of the reference RNA were originally quantified by the manufacturer in ng/μL of total RNA. Ten-fold dilutions from 1 ng/μL to 0.01 pg/μL RNA were tested in triplicate on a single run. Using the standard curve generated with dilutions of plasmid DNA, the concentration in DENV complementary DNA (cDNA) equivalents/μL was calculated for the highest concentration of RNA (1 ng/μL) for each serotype. Dilutions were performed on a single day for each serotype. The linear range was established by fitting a best-fit line to the data by regression analysis and included the range where the R² value for this line was ≥0.99.

To establish the lower limit of 95% detection (95% LLOD), the lowest concentrations of RNA at which all five replicates were detectable during the linear range study were used as the starting point. Ten replicates of four, two-fold dilutions were tested in a single run. The 95% LLOD was then calculated using probit analysis. Analytical sensitivity for the multiplex assay was compared to the reference hemi-nested RT-PCR. The dilutions made for the test of linearity using RNA were added to the RT-PCR step of the hemi-nested PCR. Each 10-fold dilution was run in duplicate in the reference assay.

The precision of the multiplex rRT-PCR assay was determined using three dilutions of RNA controls (high positive, low positive, and limit of quantitation). These were performed as 5 replicates on 3 separate days. Fresh dilutions were made on the day of each run from aliquots of high concentration stocks (1 ng/μL, high positive). Intra- and inter-run variability was calculated from the log10-concentration of the samples, except where indicated.

**Multiplex rRT-PCR Specificity**

Specificity was evaluated by testing genomic RNA from WNV, JEV, and TBEV isolates, as well as from the yellow fever 17D (YF-17D) vaccine strain. The JEV, TBEV, and WNV strains are described above. For YF-17D, genomic RNA (Virxcell; Grenada, Spain) was tested at concentrations of at least 12,500 copies/μL and 250 copies/μL, as quantitated by the manufacturer. In addition, multiplex rRT-PCR assay specificity was determined by testing 80 patient plasma samples, 60 hepatitis C virus (HCV)-positive and 20 HCV-negative, sent to the Stanford Clinical Virology Laboratory for HCV viral load testing.

**Mixing Studies**

Interference was evaluated by performing mixing studies using dilutions of quantitated plasmid. All dual-infection combinations were simulated using 2.0 log10 copies/μL of a given serotype mixed with serial, 10-fold dilutions of a second serotype extending from 5.0 to 2.0 log10 copies/μL. DENV-1 and -4 dual infections were differentiated from DENV-1 mono-infection based on Ct differences between the green and red channels.

**Clinical Participants**

Seventy-four archived, de-identified samples from suspected dengue patients presenting within the first five days of clinical illness were tested. These samples were collected between September 9, 2009 and December 8, 2011 as part of the Nicaraguan Pediatric Dengue Cohort Study as well as a hospital-based study to assess risk factors for severe dengue in inpatients of the Infectious Diseases Ward of the Hospital Infantil Manuel de Jesús Rivera (Managua, Nicaragua). Study design and methods for both of these studies have been previously described [32–34]. All patients were clinically suspected of having dengue fever and had been tested using an earlier version of the hemi-nested RT-PCR assay [13]. RNA was extracted from separate aliquots of plasma stored at −80°C and tested, during a single freeze-thaw cycle, using the DENV multiplex rRT-PCR and the reference assay.

Forty de-identified plasma samples from children presenting to the Lady Ridgeway Hospital (Colombo, Sri Lanka) with an acute febrile illness were also tested. These samples were collected prospectively from March 18 to May 28, 2012. These patients were clinically diagnosed with DF, DHF, or DSS according to the WHO 1997 recommendations [4]. Patients were tested with the
concentration in DENV cDNA equivalents/standard curves generated with dilutions of plasmid DNA, the range of the multiplex assay therefore corresponds to the following concentration of RNA was determined for each serotype. The linear range extended from 7.0 to 1.0 log10 copies/mL for DENV-1, -2, and -3, and from 7.0 to 2.0 log10 copies/mL for DENV-4 (Figure 1). Using plasmid DNA, the linear range for each serotype was 76,000 cDNA equivalents/μL (2 of 2 replicates) for DENV-1, 79,000 (2 of 2 replicates) for DENV-2, 224 (1 of 2 replicates) for DENV-3, and 16 (1 of 2 replicates) for DENV-4. Given the comparatively poor analytical sensitivity of the NS5 TaqMan assay, it was not tested in further experiments.

Results

Nucleic Acid Extraction of Clinical Specimens

Nucleic acid extraction was performed using the QIAamp Viral RNA Mini Kit (Qiagen; Valencia, CA). All extractions were carried out according to the manufacturer’s recommendations. Extractions were performed using 140 μL of patient plasma, eluted into 60 μL of buffer AVE. The quantitation of clinical specimens in cDNA equivalents/μL serum or plasma took into account these extraction and elution volumes and was calculated using the following formula: (cDNA equivalents/μL * 60 μL)/(0.14 mL).

Ethics

The protocols for the Nicaraguan Pediatric Dengue Cohort Study and Pediatric Hospital-based Dengue Study were reviewed and approved by the Institutional Review Boards (IRB) of the University of California, Berkeley, and the Nicaraguan Ministry of Health. Parents or legal guardians of all subjects provided written informed consent, and subjects 6 years of age and older provided assent. The IRB at Stanford University waived review of this study, as samples were pre-collected and de-identified.

Statistics

Basic statistical analysis including the calculation of means and standard deviation was performed using Excel software (Microsoft; Bellevue, WA). Two-tailed Fisher’s exact tests, t-tests, and kappa calculations were performed using GraphPad software (GraphPad; La Jolla, CA). Probit analysis was performed using SPSS (IBM; Armonk, NY).

Results

Linearity and Lower Limit of Detection

The primers and probe sets used in the multiplex assay are shown in Tables 1 and 2, respectively. The probes differ by one to four bases between the different serotypes and are listed by the channel in which they are detected. The pattern of signal obtained from the different probes for each serotype is displayed in Table 3. Using DENV reference RNA dilutions, the linear range for each serotype extended from 1.0 ng RNA/μL to 0.01 pg RNA/μL. Based on standard curves generated with dilutions of plasmid DNA, the concentration in DENV cDNA equivalents/μL for the highest concentration of RNA was determined for each serotype. The linear range of the multiplex assay therefore corresponds to the following cDNA equivalents/μL: DENV-1, 5.8 to 0.8 log10; DENV-2, 6.6 to 1.6 log10; DENV-3, 5.3 to 0.3 log10; DENV-4, 5.9 to 0.9 log10 (Figure 1). Using plasmid DNA, the linear range for each serotype extended from 7.0 to 1.0 log10 copies/μL for DENV-1, -2, and -3, and from 7.0 to 2.0 log10 copies/μL for DENV-4 (data not shown).

The lower limit of 95% detection (LLOD) was determined for each serotype in the multiplex assay by probit analysis using reference RNA dilutions. The LLOD was calculated to be 0.3 cDNA equivalents/μL for DENV-1, 13.8 for DENV-2, 0.8 for DENV-3, and 12.4 for DENV-4. For comparison, duplicates of the same RNA dilutions were run on the same day, using the hemi-nested RT-PCR reference assay. The lowest concentrations detected by the reference assay were 6 cDNA equivalents/μL for DENV-1, 3800 (2 of 2 replicates) for DENV-2, 21 (1 of 2 replicates) for DENV-3, and 79 (1 of 2 replicates) for DENV-4. The multiplex rRT-PCR assay, therefore, was more analytically sensitive for each serotype than the reference assay.

We initially intended to compare our multiplex rRT-PCR with a multiplex, hydrolysis probe-based rRT-PCR targeting the DENV NS5 gene (NS5 TaqMan). Therefore, this NS5 TaqMan assay was also evaluated using duplicates of 10-fold RNA dilutions. The lowest concentrations detected by the NS5 TaqMan assay were 76,000 cDNA equivalents/μL (2 of 2 replicates) for DENV-1, 89,000 (2 of 2 replicates) for DENV-2, 224 (1 of 2 replicates) for DENV-3, and 16 (1 of 2 replicates) for DENV-4. Given the comparatively poor analytical sensitivity of the NS5 TaqMan assay, it was not tested in further experiments.

Precision

Both intra- and inter-run precision were calculated for each serotype at three concentrations (high-positive, low-positive, and limit-of-quantitation) using reference RNA. These calculations were performed using the log10 cDNA equivalents/μL for each sample, except for DENV-3 at the limit of quantitation, where the mean concentration and precision calculations were expressed on the linear scale. Each mean concentration as well as intra- and inter-run precision are shown in Table 4.

Mixed Infection

DENV plasmids were mixed at known concentrations to simulate infections involving two different serotypes. Dual infections were detected for all serotype combinations when mixed at equal concentrations (data not shown). For each serotype, tested at the limit of quantitation, amplification was inhibited by 10 to 1000-fold higher concentrations of the competing serotype.

Specificity

Genomic RNA from one strain each of JEV and TBEV, three strains of WNV, and high and low concentrations of YF-17D showed no detectable signal in the multiplex rRT-PCR. Eighty archived patient samples that had previously been sent for HCV testing (60 positive and 20 negative samples) were also tested. The positive samples had a median HCV viral load of 6.05 log10 copies/mL (range 1.63–7.66 log10 copies/mL). These samples also showed no detectable signal in the multiplex rRT-PCR assay.

As a further test of specificity, the primers and probes were tested in silico by querying the NCBI nucleotide database for related sequences. The best, non-DENV matches for the primer and probe sets used in the multiplex assay are shown in Table 3. Using the Flaviviridae showed only 50–68% coverage. No organism represented the best match for both the forward and reverse primers for any of our primer pairs. For the probes, certain JEV strains had 56–91% coverage, though these sequences would not be predicted to amplify using the primers in this assay.

Clinical Samples

Seventy-four archived plasma samples that were collected from Nicaraguan children within the first five days of a dengue-like illness were tested using both the multiplex rRT-PCR and the reference hemi-nested assay. The mean day of illness for patients in this group was 3.39 (standard deviation, 1.25). The two assays showed good agreement (Table 3, kappa = 0.737). The multiplex rRT-PCR was positive in 100% (69/69) of samples with detectable...
DENV RNA in the reference assay. There was complete agreement in the serotyping calls between the two assays (22 DENV-1, 12 DENV-2, 35 DENV-3). An additional two samples had detectable DENV RNA by the multiplex rRT-PCR but were negative by the reference assay (1 DENV-1, 1 DENV-3). Three samples tested negative by both assays.

Forty plasma samples were obtained from children in Sri Lanka with a clinical diagnosis of dengue, collected prospectively during a single dengue season. Thirty-six patients had detectable anti-DENV IgM antibodies at diagnosis (90%). These samples were tested using both the multiplex rRT-PCR and the reference hemi-nested assay. The multiplex rRT-PCR was positive in 95.0% of patients (38/40, 37 DENV-1 and 1 DENV-3), whereas the reference assay was positive in only 40.0% (16/40, 16 DENV-1). All samples detected by the reference assay were also detected by the multiplex rRT-PCR. In the 36 patients with detectable IgM antibodies, the multiplex rRT-PCR was positive in 97.2% (35/36) whereas the reference assay was positive in only 44.4% (16/36). Amplicons from four multiplex rRT-PCR-positive, reference assay-negative samples were cloned and sequenced, confirming the specific amplification of DENV RNA. The samples contained similar levels of RNase P RNA, verifying adequate extraction and the absence of RT-PCR inhibitors (data not shown).

The composition of the groups of patients from Sri Lanka who were positive by the DENV multiplex rRT-PCR alone and positive by both assays is shown in Table 6. These two groups were generally similar. However, patients who tested positive only by the multiplex rRT-PCR were more likely to have secondary dengue (p = 0.047), and they had a lower average viral load (p = 0.0002). Two of the forty patients tested negative by both assays. One patient was clinically diagnosed with DF and had a positive IgM test on day 5 of illness. The second patient was diagnosed with an undifferentiated febrile illness and tested IgM negative on day seven of illness. A single patient died; their viral load was 3.2 log_{10} cDNA equivalents/mL on day of illness seven. Overall, the multiplex rRT-PCR detected 100% (85/85) of the samples detected by the reference assay, with perfect serotype agreement. Furthermore, the multiplex rRT-PCR identified DENV RNA in 24 additional clinical specimens from patients with known recent DENV infection.

**Discussion**

This study describes the development of a single-reaction, multiplex rRT-PCR for the detection, quantitation, and serotyping of dengue viruses from patient samples. Analytical and clinical
evaluation of the assay was performed using reference RNA that included the four DENV serotypes and other closely related flaviviruses, as well as clinical specimens from Nicaragua, Sri Lanka, and the United States.

The DENV multiplex rRT-PCR was compared to a version of a hemi-nested RT-PCR that has been in use for at least two decades and continues to be performed in laboratories throughout the world [12,13,25]. To our knowledge only two single-reaction rRT-PCR assays with serotyping capability have been directly compared to another nucleic acid amplification test, and in both reports, the hemi-nested RT-PCR was used as reference. In both cases, the hemi-nested assay proved more sensitive [12,16]. Johnson, et al. describes the development of another multiplex PCR-ligase detection reaction for DENV compared favorably to the NS5 TaqMan assay, but this assay involves a complicated one component of a larger multiplex assay to detect eight different flaviviruses [14,22,35]. We therefore initially selected this assay to compare to our multiplex rRT-PCR. In our hands, this assay was at least 200-fold less analytically sensitive than the hemi-nested RT-PCR using reference RNA for DENV-1 and -3. Because of this relatively poor sensitivity, we did not utilize the NS5 TaqMan assay as reference.

In this study, we demonstrate that the DENV multiplex rRT-PCR is more analytically sensitive than the reference hemi-nested RT-PCR. Consistent with this finding, DENV RNA was detectable in more patient specimens using the multiplex rRT-PCR (95.6%; 109/114) than the reference assay (74.6%; 85/114). This difference is primarily accounted for by viral RNA detection in specimens positive for DENV IgM (22 specimens). In previous studies, such samples are often not tested, given low rates of RT-PCR positivity, and assays are typically evaluated using samples positive by viral isolation [12,14,16–20,23]. In the report by Kong, et al., IgM-positive samples were tested, but only 69% were positive for DENV RNA by their assay. The rate of detection dropped to below 10% by day five of illness [17]. In contrast, our DENV multiplex rRT-PCR maintained a sensitivity of 97.2% (35/36) for the diagnosis of dengue even after the development of IgM antibodies, which may lengthen the period of time during which a patient can receive a virologically confirmed, serotype-specific diagnosis of dengue. Despite this sensitivity, the DENV multiplex rRT-PCR was specific for dengue viruses and did not amplify related flaviviruses, even at very high viral loads.

A number of other multiplex, serotype-specific rRT-PCR assays have previously been described in the literature, but they all have specific limitations compared to the assay reported here. An RT-PCR-ligase detection reaction for DENV compared favorably to the NS5 TaqMan rRT-PCR, but this assay involves a complicated design including lab-developed microarray detection that is not commonly used even in very sophisticated molecular virology laboratories [14]. The hydrolysis probe-based rRT-PCR assays

<table>
<thead>
<tr>
<th>Table 4. Precision analysis of the DENV multiplex rRT-PCR.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>DENV-1</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>DENV-2</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>DENV-3</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>DENV-4</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

*Expressed as cDNA equivalents/µL.
SD, standard deviation; %CoV, percent coefficient of variation.
doi:10.1371/journal.pntd.0002116.t004

<table>
<thead>
<tr>
<th>Table 5. Comparison of samples collected from patients in Nicaragua presenting within the first five days of a dengue-like illness.</th>
</tr>
</thead>
<tbody>
<tr>
<td>DENV</td>
</tr>
<tr>
<td>Multiplex</td>
</tr>
<tr>
<td>Positive</td>
</tr>
<tr>
<td>Negative</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>
doi:10.1371/journal.pntd.0002116.t005
Table 6. Comparison of patients from Sri Lanka that tested positive only by the multiplex rRT-PCR and those that tested positive by both the multiplex rRT-PCR and reference assays.

<table>
<thead>
<tr>
<th></th>
<th>Multiplex rRT-PCR Positive</th>
<th>Multiplex rRT-PCR Positive</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reference Method Negative</td>
<td>Reference Method Positive</td>
<td></td>
</tr>
<tr>
<td><strong>Patients, n (%)</strong></td>
<td>22 (55)</td>
<td>16 (40)</td>
<td>ND</td>
</tr>
<tr>
<td><strong>Age, mean (SD)</strong></td>
<td>7.1 (3.6)</td>
<td>6.1 (4.0)</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Day of Illness, mean (SD)</strong></td>
<td>5.8 (1.6)</td>
<td>6.1 (1.2)</td>
<td>0.53</td>
</tr>
<tr>
<td><strong>IgM Positive, n (%)</strong></td>
<td>19 (86)</td>
<td>16 (100)</td>
<td>0.25</td>
</tr>
<tr>
<td><strong>Primary Dengue, n (%)</strong></td>
<td>7 (32)</td>
<td>11 (69)</td>
<td>0.047</td>
</tr>
<tr>
<td><strong>Illness Severity, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DF</td>
<td>15 (68)</td>
<td>6 (38)</td>
<td>0.10</td>
</tr>
<tr>
<td>DHF/DSS</td>
<td>7 (32)</td>
<td>10 (62)</td>
<td></td>
</tr>
<tr>
<td>Any ICU Care, n (%)</td>
<td>4 (18)</td>
<td>7 (44)</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>Viral Load, mean (SD)</strong></td>
<td>2.98 (0.61)</td>
<td>4.4 (1.41)</td>
<td>0.0002</td>
</tr>
</tbody>
</table>

*Viral Load expressed as log_{10} cDNA equivalents/mL of patient plasma.
ND, not determined; SD, standard deviation.

doi:10.1371/journal.pntd.0002116.t006

reported by Kong, et al. and Lai, et al. showed promising results, but were designed using very small numbers of DENV sequences, raising concerns regarding their generalizability [17,18]. Indeed, the assay by Lai, et al. was used in a study of DENV and chikungunya virus in Tanzania, where none of the 71 patients with presumptive, acute DENV infections based on IgM detection had detectable DENV RNA. The median day of illness for these patients was 4.5 (IQR 3–14) [36]. Multiplex rRT-PCR assays that utilize melting curves for serotyping do not clearly distinguish between serotypes, whereas other assays require multiple reactions to achieve accurate serotyping [15,19,23]. Recently, the United States Food and Drug Administration (FDA) approved a single-reaction, multiplex rRT-PCR developed by the Centers for Disease Control and Prevention (CDC), but this assay was not available for evaluation at the time of our study [37].

Further benefits of the DENV multiplex rRT-PCR include its single-reaction set-up and a reaction set-up-to-result time that is much shorter than the hemi-nested PCR (3 hrs. vs. 10 hrs.). The real-time design of this assay allows for faster results than the reference assay, though it does not provide a result as rapidly as point-of-care diagnostics such as NS1 and IgM lateral flow detection kits. These rapid antigen and antibody assays do not require the laboratory infrastructure necessary to perform RT-PCR, but they also cannot provide the amount of information available from a serotype-specific multiplex rRT-PCR [9]. Assay cost has also been cited as another advantage of rapid diagnostics. As reported here, the cost of the DENV multiplex rRT-PCR is 2.60 USD per reaction plus 4.00 USD for RNA extraction, which compares favorably to the cost of the rapid assay utilized in this study (6.00 USD, Dr. Abeynayake, personal communication).

The assay described herein was designed as a quantitative test for DENV. Though the clinical utility of viral load testing in the management of patients with DF remains unclear, previous studies have shown that patients with higher viral loads are at an increased risk for severe disease [38,39]. Vaughn, et al. showed that peak viremia, when identified, correlated with severe disease in children infected with DENV-1 and DENV-2 [38]. It has also been shown that detectable viremia on the day of defervescence identifies patients at an increased risk for DHF [40]. In addition, studies have shown higher levels of peak viremia in secondary infection but also suggest that there may be differences based on the serotype of the causative DENV strain [41,42]. Identifying clinically meaningful thresholds by quantitative rRT-PCR, may, then, be serotype-specific.

Mixed infections with two or more DENV serotypes have been documented in the literature since 1985, the first of which involved a case from the 1982 DENV outbreak in Puerto Rico [43]. Mixed infections have since been reported in other regions that experience the co-circulation of multiple DENV serotypes, and the rates of such cases have varied from 0 to 56.8% of patients presenting with symptomatic DF [44–49]. All combinations of dual infections with two DENV serotype were simulated in this study by mixing known concentrations of plasmid cDNA. The DENV multiplex rRT-PCR was able to detect both serotypes in all combinations when mixed at equal concentrations. The clinical significance of mixed infections remains unclear, though it does not appear that patients with such infections are at increased risk of developing severe dengue [43,47].

This study involved a rigorous laboratory evaluation of the DENV multiplex rRT-PCR, which was designed using more than 500 DENV sequences from varied geographic locations over the past twenty years. While this design strategy should improve the generalizability of these results, the study is limited by the absence of clinical samples positive for DENV-4. As with any nucleic acid-based detection method, this assay may also be affected by the emergence of diversity in the target sequences. Though the assay is quantitative, further studies using serial samples collected over the course of a patient’s illness will need to be performed in order to show that it can be used for the monitoring of dengue viral loads.

In summary, this study describes a single-reaction, multiplex rRT-PCR for the detection, quantitation, and serotyping of dengue viruses from patient serum or plasma. This assay is more analytically sensitive than the reference molecular assay, and clinically, was able to detect and serotype virus late in the clinical course of patients with detectable anti-dengue IgM antibodies. This assay makes an important contribution to available dengue diagnostics and warrants further study in additional cohorts of dengue patients.

Supporting Information

Checklist S1 STAndards for the Reporting of Diagnostic accuracy studies (STARD) checklist. (DOC)

Figure S1 STAndards for the Reporting of Diagnostic accuracy studies (STARD) flowchart. (EPS)

Acknowledgments

We would like to thank the Stanford SPARK program, and in particular Drs. Kevin Grimes, Daria Mochly-Rosen, and Emily Egeler, for the tremendous support we have received throughout the course of this project. We also thank Drs. Niaz Banaei and Shirin Einav for their thoughtful comments, Dr. Matthew Anderson for graciously allowing us to use equipment for the quantitation of plasmid DNA, and Alicia Solis for helping to arrange our visit to Managua. Finally, we thank the staff of the Stanford Clinical Virology Laboratory for their ongoing support and assistance.

Author Contributions

Conceived and designed the experiments: JJW BAP. Performed the experiments: JJW JA MKS FPG YT KG GB. Analyzed the data: JJW BAP. Contributed reagents/materials/analysis tools: JA AMP LG PG VS AB KK EH. Wrote the paper: JJW BAP.
References


